Emerging Radioligand Therapies

Sep 14, 2026

Summary Novartis faced an unusually difficult period in late August–September 2026, with two Phase 3 programs (pelacarsen and del-desiran) failing their primary endpoints and eight rap-cel autoimmune trials paused following three patient deaths. The back-to-back setbacks triggered a sharp market response, wi...

Apr 13, 2026

Summary  With FDA-approved products LUTATHERA and PLUVICTO, both beta-emitters, Novartis has established itself as an industry frontrunner. Over 15 ongoing or planned trials and several next-generation candidates in development in Novartis RLT pipeline. Rivals include AstraZeneca, Bayer, Eli Lilly, C...

Mar 20, 2026

Summary Radioligand therapy is quickly establishing itself as a transformative force in oncology, with demand accelerating so rapidly that manufacturers are under pressure to scale up production. Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive lan...